drugset / Trial / NCT02264067

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) in Healthy Male Volunteers

NCT02264067

Phase 1 Completed 36 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the pharmacokinetics and safety of WAL2014 capsules administered orally as a single dose to healthy adult male volunteers in double blind manner.

Timeline

Start
1998-07
Primary completion
1998-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Talsaclidine Small molecule Oral

Indications

No indication recorded.